To explore the potential of using cell-free DNA (cfDNA) to identify genetic and epigenetic changes that may herald a transition to cancer, the Dawson lab at the Peter MacCallum Cancer Centre and University of Melbourne used the duet multiomics solution evoC to generate a 6-base genome from a cohort of healthy, CLD, and HCC patients across a range of disease stages.
This study suggests that profiling cfDNA with duet evoC would be very useful for the analysis of liquid biopsy samples to generate biologically relevant data for exploring early detection and disease progression in HCC.
